Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...
Stockhead on MSN9h
Health Check: Awaiting key announcements, these biotechs could use some Irish luck
On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...
manilatimes19d
Opthea Completes Drug Product PPQ Campaign
"The successful completion of the drug product PPQ campaign is a critical step in support of a potential BLA filing of sozinibercept in wet AMD in the first half of CY2026,” commented Fred Guerard, ...
Science Daily18d
Stem cell transplant clears clinical safety hurdle for the treatment of wet age-related macular degeneration
Wet AMD in its early stages can be treated with drugs to reduce the formation of new blood vessels, but this treatment is inefficient in cases where blood vessel formation is already in its advanced ...
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's ...
Yahoo Finance17d
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration Outlook Therapeutics, Inc. Fri, Feb 28, 2025, 8:05 ...
Morningstar11d
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
Recognizing that wet AMD patients require individualized treatment ... axitinib behind the retina, thereby limiting drug exposure to the front of the eye. About Clearside’s Suprachoroidal ...
Nasdaq10d
Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA Meeting
The wet AMD market exceeds $12 billion ... minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension ...
Morningstar17d
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
“We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the ...